Commercializing a breakthrough advance in inflammation science. MORE
Antibe Therapeutics is a publicly traded biotechnology company exploiting groundbreaking advances in inflammation science.
Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation
Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors
Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing
Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Antibe Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit